{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:34:35Z","timestamp":1792895675239,"version":"4.5.0"},"reference-count":28,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie Spain Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Even though venetoclax in combination with azacitidine (VenAza) is considered a low-intensity regimen, its patients present a high incidence of cytopenia and infections during the first courses, making the initial management a challenging phase. Methods: This difficulty in our center led to the establishment of an At-Home (AH) program for ramp-up and follow-up patients during the VenAza combination induction phase focused on therapy administration, patient and caregiver education, and management of adverse events (AEs). A total of 70 patients with newly diagnosed acute myeloid leukemia (ND-AML) or relapsed\/refractory AML (R\/R AML) were treated with VenAza from March 2019 to May 2022. We compared outcomes between patients managed with a hospital-based (inpatient) approach and those managed through the AH program. Results: Despite most patients experiencing grade 3\u20134 cytopenias (96.9%), the incidence of serious infections and other AEs was comparable between both groups, with no significant difference in febrile neutropenia (42.3% vs. 27.8%, p = 0.38). Overall, the AH cohort demonstrated a significantly lower hospital readmission rate after ramp-up (29.5% vs. 84.6%, p = 0.001). Moreover, the inpatient cohort\u2019s admission days were longer than in the AH cohort (13 vs. 8, p = 0.28). Conclusions: AH management was feasible and safe, leading to better resource use, enhanced patient comfort, and improved treatment compliance. The potential of AH programs for managing low-intensity chemotherapy regimens can reduce hospital admissions and subsequently improve patient and caregiver well-being.<\/jats:p>","DOI":"10.3390\/cancers16244274","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T09:13:38Z","timestamp":1734945218000},"page":"4274","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-5356","authenticated-orcid":false,"given":"Alexandra","family":"Mart\u00ednez-Roca","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Home Care and Bone Marrow Transplantation Unit, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Medicine, Faculty of Medicine and Health Sciences, University of Barcelona, 08007 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9548-4305","authenticated-orcid":false,"given":"Carlos","family":"Jim\u00e9nez-Vicente","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Home Care and Bone Marrow Transplantation Unit, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Medicine, Faculty of Medicine and Health Sciences, University of Barcelona, 08007 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Merch\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Home Care and Bone Marrow Transplantation Unit, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9044-4665","authenticated-orcid":false,"given":"Sandra","family":"Casta\u00f1o-Diez","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Hemopathology Unit, Pathology Department, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7666-5055","authenticated-orcid":false,"given":"In\u00e9s","family":"Zugasti","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Brillembourg","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lex","family":"Bataller","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Hemopathology Unit, Pathology Department, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6376-0929","authenticated-orcid":false,"given":"Francesca","family":"Guijarro","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Hemopathology Unit, Pathology Department, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Cort\u00e9s-Bullich","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Trigueros","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Isabel","family":"P\u00e9rez-Valencia","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gallego","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Home Care and Bone Marrow Transplantation Unit, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7841-0171","authenticated-orcid":false,"given":"Nuria","family":"Ballestar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Home Care and Bone Marrow Transplantation Unit, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Carcelero","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Division of Medicine, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"D\u00edaz-Bey\u00e1","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Medicine, Faculty of Medicine and Health Sciences, University of Barcelona, 08007 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Medicine, Faculty of Medicine and Health Sciences, University of Barcelona, 08007 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3733-590X","authenticated-orcid":false,"given":"Francesc","family":"Fern\u00e1ndez-Avil\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Home Care and Bone Marrow Transplantation Unit, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Medicine, Faculty of Medicine and Health Sciences, University of Barcelona, 08007 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"Dinardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1200\/JCO.23.01599","article-title":"Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML with Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)","volume":"42","author":"Tiong","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/bloodadvances.2023011106","article-title":"Venetoclax\u2013based low intensity therapy in molecular failure of NPM1-mutated AML","volume":"8","author":"Othman","year":"2024","journal-title":"Blood Adv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"107403","DOI":"10.1016\/j.leukres.2023.107403","article-title":"Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF","volume":"135","author":"Pomares","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"111-e1","DOI":"10.1016\/j.jtct.2022.11.018","article-title":"Feasibility of a Hospital-at-Home Program for Autologous Hematopoietic Stem Cell Transplantation","volume":"29","author":"Calvo","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1200\/JCO.2006.06.4238","article-title":"Case-Control Comparison of At-Home to Total Hospital Care for Autologous Stem-Cell Transplantation for Hematologic Malignancies","volume":"24","author":"Carreras","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e0241778","DOI":"10.1371\/journal.pone.0241778","article-title":"The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever","volume":"15","author":"Pedraza","year":"2020","journal-title":"PLoS ONE"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Garc\u00e9s-Carrasco, A.M., Santacatalina-Roig, E., Carretero-M\u00e1rquez, C., Chover-Sierra, E., Mart\u00ednez-Sabater, A., and Balaguer-L\u00f3pez, E. (2023). Post-Transplant Complications in Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT)\u2014A Comparative Analysis of Home Care versus Hospitalized Patients. Medicina, 60.","DOI":"10.3390\/medicina60010044"},{"key":"ref_15","first-page":"832","article-title":"Pilot Trial of Homebound Hematopoietic Cell Transplantation","volume":"28","author":"Landau","year":"2022","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ejh.13753","article-title":"Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents","volume":"108","author":"Papayannidis","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1007\/s00520-021-06119-7","article-title":"Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia","volume":"29","author":"Pelcovits","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1177\/10781552221142872","article-title":"Outpatient initiation of venetoclax in patients with acute myeloid leukemia","volume":"29","author":"Palmer","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e0254135","DOI":"10.1371\/journal.pone.0254135","article-title":"Hospital and outpatient models for Hematopoietic Stem Cell Transplantation: A systematic review of comparative studies for health outcomes, experience of care and costs","volume":"16","author":"Urizar","year":"2021","journal-title":"PLoS ONE"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.medcli.2017.04.019","article-title":"Feasibility and cost-effectiveness of at home azacitidine administration","volume":"149","author":"Sampol","year":"2017","journal-title":"Med. Clin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41375-022-01556-7","article-title":"Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)","volume":"36","author":"Maschmeyer","year":"2022","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"3","author":"Aldoss","year":"2019","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1007\/s00277-024-05923-5","article-title":"Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: A real-life study","volume":"103","author":"Guijarro","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.3109\/09638288.2012.683479","article-title":"Validity and variability of the 5-repetition sit-to-stand test in patients with multiple sclerosis","volume":"34","author":"Bibby","year":"2012","journal-title":"Disabil. Rehabil."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/bloodadvances.2022007333","article-title":"Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents","volume":"6","author":"Johnson","year":"2022","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41409-019-0768-x","article-title":"A reproducible and safe at-home allogeneic haematopoietic cell transplant program: First experience in Central and Southern Europe","volume":"55","author":"Rovira","year":"2020","journal-title":"Bone Marrow Transplant."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4274\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:58:13Z","timestamp":1760115493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":28,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["cancers16244274"],"URL":"https:\/\/doi.org\/10.3390\/cancers16244274","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]}}}